This review summarizes the biology of VEGF and ANG2 signaling, mechanisms of vascular normalization, preclinical and clinical evidence of VEGF/ANG2 bispecific antibodies, and current and future therapeutic applications in breast cancer, highlighting their potential to enhance multimodal treatment efficacy and improve patient outcomes. Here, VEGFA is linked to breast carcinoma.